Health Care & Hospital Law,
Civil Litigation,
Antitrust & Trade Reg.
Nov. 8, 2021
Bristol-Myers Squibb settles antitrust class action for $10M
Although they will not seek fees from the $10 million fund, attorneys representing pension funds leading the case seek $2.5 million for litigation expenses. They said they have incurred more than $3.3 million in such expenses.
Bristol-Myers Squibb has settled for $10 million an antitrust class action accusing it and alleged co-conspirators Gilead and Janssen of blocking generic versions of their HIV drugs, according to a court filing.
The agreement includes no finding of fault by the company.
As part of the deal filed on Thursday for preliminary approval, BMS agreed to waive a no-generics restraint in its contract with Gilead for Evot...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In
